Yissum Research Development Company of the Hebrew University of Jerusalem Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Yissum Research Development Company of the Hebrew University of Jerusalem Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011831
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd (YRDC) is a technology transfer company that offers marketing the inventions and know-how generated by the University’s researchers and students. The company’s products include exelon, doxil, cherry tomatoes and long shelf-life tomatoes, granagard, osmoter x6 facial serum, hybrid peppers, hygia nutrients, artichoke, cationorm, agcite, vuze, melon, periochip, ikervis, explora, superior ceramic ink, uv-pearl, seer, and bioresorbable adhesion barrier. Its exelon is a cholinesterase inhibitor medicine for people in the early or middle stages of Alzheimer’s disease. YRDC transfers the technologies in various fields including computer science, medicine and pharmaceuticals, nanotechnology, water and environmental technologies, agriculture and nutrition, and homeland security, among others. The company supports business partners in identifying the expert researcher to conduct the research and tailor the partnerships to the requirements of the business partner and the technologies. YRDC is headquartered in Givat Ram, Israel.

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
Atox Bio Raises USD30 Million in Financing 16
Avraham Pharma Raises up to USD4.5 Million Financing 18
Avraham Pharma Raises USD4.5 Million in Venture Financing 19
Avraham Pharma Raises US$6 Million In Venture Financing 21
Integra Holdings Raises US$7 Million In First Round Financing 23
Avraham Pharma Secures US$3 Million In Venture Financing 24
Partnerships 25
Phytecs Enters into Agreement with Yissum Research Development 25
Kamada Enters into Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 26
Accurexa Enters into Agreement with Yissum Research Development 27
Yissum Research Development Expands Licensing Agreement with Israel Chemicals 28
Licensing Agreements 29
Therapix Biosciences Licensing Agreement with Yissum Research Development Company 29
BioLineRx Enters into Licensing Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 30
Spherium Biomed Enters into Option Agreement with Yissum 31
BioTheryX Enters into Licensing Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 32
Immune Pharma Enters into Licensing Agreement with Yissum 33
Kalytera Therapeutics Enters into Licensing Agreement with Yissum Research Development Company 35
Immune Pharma Enters into Licensing Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 36
BioCancell Amends Licensing Agreement With Yissum Research Development 37
Therapix Biosciences to Enter into Licensing Agreement with Yissum Research Development Company 38
Immune Pharma to Enter into Licensing Agreement with Yissum Research Development 39
Yissum Research Development, Hadasit and Kennedy Trust Enter into Licensing Agreement with ISA Scientific 40
Yissum Research Development Enters into Licensing Agreement with PhytoTech Medical 41
BioLineRx Enters Into Licensing Agreement With Yissum, B.G. Negev Technologies And Hadasit Medical 42
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-7040 44
Acquisition 45
Guangxi Wuzhou Zhongheng Invests USD3 Million in Integra 45
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd – Key Competitors 46
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd – Key Employees 47
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd – Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Recent Developments 49
Strategy And Business Planning 49
Mar 14, 2016: Yissum Forms Neteera Technologies for Remote Sensing of Biological Indicators 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Deals By Therapy Area, 2011 to YTD 2017 10
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Atox Bio Raises USD30 Million in Financing 16
Avraham Pharma Raises up to USD4.5 Million Financing 18
Avraham Pharma Raises USD4.5 Million in Venture Financing 19
Avraham Pharma Raises US$6 Million In Venture Financing 21
Integra Holdings Raises US$7 Million In First Round Financing 23
Avraham Pharma Secures US$3 Million In Venture Financing 24
Phytecs Enters into Agreement with Yissum Research Development 25
Kamada Enters into Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 26
Accurexa Enters into Agreement with Yissum Research Development 27
Yissum Research Development Expands Licensing Agreement with Israel Chemicals 28
Therapix Biosciences Licensing Agreement with Yissum Research Development Company 29
BioLineRx Enters into Licensing Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 30
Spherium Biomed Enters into Option Agreement with Yissum 31
BioTheryX Enters into Licensing Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 32
Immune Pharma Enters into Licensing Agreement with Yissum 33
Kalytera Therapeutics Enters into Licensing Agreement with Yissum Research Development Company 35
Immune Pharma Enters into Licensing Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 36
BioCancell Amends Licensing Agreement With Yissum Research Development 37
Therapix Biosciences to Enter into Licensing Agreement with Yissum Research Development Company 38
Immune Pharma to Enter into Licensing Agreement with Yissum Research Development 39
Yissum Research Development, Hadasit and Kennedy Trust Enter into Licensing Agreement with ISA Scientific 40
Yissum Research Development Enters into Licensing Agreement with PhytoTech Medical 41
BioLineRx Enters Into Licensing Agreement With Yissum, B.G. Negev Technologies And Hadasit Medical 42
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-7040 44
Guangxi Wuzhou Zhongheng Invests USD3 Million in Integra 45
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Key Competitors 46
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Key Employees 47
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, Subsidiaries 48

★海外企業調査レポート[Yissum Research Development Company of the Hebrew University of Jerusalem Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Oramed Pharmaceuticals Inc (ORMP):製薬・医療:M&Aディール及び事業提携情報
    Summary Oramed Pharmaceuticals Inc (Oramed) engages in the research and development of novel pharmaceutical solutions, comprising an oral insulin capsule for the treatment of individuals with diabetes, and orally ingestible capsules or pills for delivery of other polypeptides. It developed a unique …
  • Applied Materials Inc (AMAT):電力:M&Aディール及び事業提携情報
    Summary Applied Materials Inc.(Applied Materials) is a provider of manufacturing equipment and software services.. The company provides semiconductors, displays, solar products, roll to roll web coating, emerging technologies and products and automation software. It caters its products and services …
  • Cypralis Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Cypralis Ltd (Cypralis), formerly Selcia Pharma Ltd is a drug developer that provides discovery and development of therapeutics targeting peptidyl-prolyl isomerases. The company spans its expertise in the development of medicines for degenerative diseases such as acute tissue injury, liver d …
  • Corgenix Medical Corp-医療機器分野:企業M&A・提携分析
    Summary Corgenix Medical Corp (Corgenix), a subsidiary of Orgentec Diagnostika GmbH is a medical device company that offers medical diagnostic solutions. The company offers vascular disease products, infectious disease products, non-invasive liver biomarkers, and instrumentation. It offers an instru …
  • Misr Hotels Co:企業の戦略・SWOT・財務分析
    Misr Hotels Co - Strategy, SWOT and Corporate Finance Report Summary Misr Hotels Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Cepheid:企業の戦略的SWOT分析
    Cepheid - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Husky Energy Inc. (HSE):企業の財務・戦略的SWOT分析
    Husky Energy Inc. (HSE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999):企業の財務・戦略的SWOT分析
    China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the …
  • GenMark Diagnostics Inc (GNMK):企業の財務・戦略的SWOT分析
    Summary GenMark Diagnostics Inc (GenMark) is a medical device company that provides clinical testing systems. The company provides products such as XT-8 systems and ePlex systems. It offers pipeline products such as eSensor 2C 19 genotyping test, eSensor HCV genotyping test, eSensor HCVg direct test …
  • FluGen Inc-製薬・医療分野:企業M&A・提携分析
    Summary FluGen Inc (FluGen) is a healthcare services provider that offers vaccine and therapies. The company discovers, develops and commercializes new methods for the prevention and treatment of influenza infections. Its product includes redeeflu that contains mutations in the M2 gene of the virus. …
  • American Gene Technologies International Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary American Gene Technologies International Inc (AGT) is a drug development company that tests and commercializes gene-based drugs. The company develops therapies for the treatment of cancer, neurological disorders, AIDS, infectious diseases, Parkinson’s diseases, diabetes, familial dysautonomi …
  • Isagenix International LLC:企業の戦略的SWOT分析
    Isagenix International LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Covestro AG (1COV):企業の財務・戦略的SWOT分析
    Covestro AG (1COV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • IDACORP, Inc.:企業の戦略・SWOT・財務分析
    IDACORP, Inc. - Strategy, SWOT and Corporate Finance Report Summary IDACORP, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Correvio Pharma Corp (COM):製薬・医療:M&Aディール及び事業提携情報
    Summary Correvio Pharma Corp(Correvio) formerly known as Cardiome Pharma Corp, is a specialty pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company’s product portfolio includes two marketed products: Brinavess, fo …
  • Chaparral Energy Inc (CHPE):石油・ガス:M&Aディール及び事業提携情報
    Summary Chaparral Energy Inc (Chaparral Energy) is an oil and gas company that produces crude oil and natural gas. The company’s business activities include exploration, development, production and operation of oil and gas properties and wells in America’s Midwest and Southwest regions. Its new oil …
  • Zenosense Inc (ZENO):医療機器:M&Aディール及び事業提携情報
    Summary Zenosense Inc (Zenosense) is a medical device company that develops transformational medical diagnostic technologies. The company develops MIDS Cardiac, a hand held cardiac diagnostic device that applies patent-protected magnetic nanoparticle detection technology used for the rapid testing o …
  • Mahindra Holidays & Resorts India Limited:企業の戦略・SWOT・財務分析
    Mahindra Holidays & Resorts India Limited - Strategy, SWOT and Corporate Finance Report Summary Mahindra Holidays & Resorts India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Targa Resources Partners LP (NGLS PR A):企業の財務・戦略的SWOT分析
    Targa Resources Partners LP (NGLS PR A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • resTORbio Inc (TORC):製薬・医療:M&Aディール及び事業提携情報
    Summary resTORbio Inc (resTORbio) a subsidiary of Puretech Health plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of aging-related diseases. Its pipeline product candidate RTB101, an orally administered, small mo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆